Sandbox ap: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 23: Line 23:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk
|-
|-
|rowspan="6" style="background:#DCDCDC;" align="center" + |IMPROVEDD Associative Score
| rowspan="14" |IMPROVEDD Score
|
|Predicted % VTE risk through 42 days
|-
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" + |0.4% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |0.4%
|-
|-
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" + |0.6% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |0.6%  
|-
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |0.8% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |0.8%  
|-
|-
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" + |1.2% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |1.2%  
|-
|-
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" + |1.6% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |1.6%  
|-
|-
| style="background:#F5F5F5;" align="center" + |5-10
| style="background:#F5F5F5;" align="center" + |5-10
| style="background:#F5F5F5;" + |2.2% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |2.2%
|-
|
|Predicted % VTE risk through 77 days
|-
|0
|0.5%
|-
|1
|0.7%
|-
|2
|1.0%
|-
|3
|1.4%
|-
|4
|1.9%
|-
|5-10
|2.75
|-
|-
| rowspan="2" style="background:#DCDCDC;" align="center" + | Padua Score
| rowspan="2" style="background:#DCDCDC;" align="center" + | Padua Score
Line 49: Line 73:
| style="background:#F5F5F5;" + |High risk for VTE
| style="background:#F5F5F5;" + |High risk for VTE
|-
|-
| rowspan="6" style="background:#DCDCDC;" align="center" + |IMPROVE score
| rowspan="7" |IMPROVE score
|
|Predicted % VTE risk through 3 months
|-
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" align="center" + |0
| style="background:#F5F5F5;" + |0.5% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |0.5%
|-
|-
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" align="center" + |1
| style="background:#F5F5F5;" + |1.0% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |1.0%  
|-
|-
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" align="center" + |2
| style="background:#F5F5F5;" + |1.7% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |1.7%  
|-
|-
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" align="center" + |3
| style="background:#F5F5F5;" + |3.1% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |3.1%  
|-
|-
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" align="center" + |4
| style="background:#F5F5F5;" + |4% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |4%  
|-
|-
| style="background:#F5F5F5;" align="center" + |5-8
| style="background:#F5F5F5;" align="center" + |5-8
| style="background:#F5F5F5;" + |11% predicted VTE risk through 3 months
| style="background:#F5F5F5;" + |11%  
|-
|rowspan="2" style="background:#DCDCDC;" align="center" + |IMPROVE bleeding risk score
| style="background:#F5F5F5;" align="center" + |<7
| style="background:#F5F5F5;" + |Not elevated risk of bleeding
|-
| style="background:#F5F5F5;" align="center" + |≥7
| style="background:#F5F5F5;" + |Elevated risk of bleeding
|-
|rowspan="3" style="background:#DCDCDC;" align="center" + |IMPROVE Associative score
| style="background:#F5F5F5;" align="center" + |0-1
| style="background:#F5F5F5;" + |Low risk for VTE
|-
| style="background:#F5F5F5;" align="center" + |2-3
| style="background:#F5F5F5;" + |Intermediate risk for VTE
|-
| style="background:#F5F5F5;" align="center" + |4-10
| style="background:#F5F5F5;" + |High risk for VTE
|-
|-
|rowspan=4 style="background:#DCDCDC;" align="center" + |Caprini score
| rowspan="4" style="background:#DCDCDC;" align="center" + |Caprini score
| style="background:#F5F5F5;" align="center" + |0-1
| style="background:#F5F5F5;" align="center" + |0-1
| style="background:#F5F5F5;" + |Low risk of VTE
| style="background:#F5F5F5;" + |Low risk of VTE
Line 100: Line 110:


==References==
==References==
<references />

Revision as of 13:07, 16 October 2017

Historical Perspective

Discovery

  • In 1869, Paul Langerhans first described pancreatic islet cells, when he was still a medical student.
  • In 1902, Nicholls discovered the first adenoma of pancreatic islets.[1]
  • In 1922, Frederick Banting and Charles Best were the first to discover insulin from a dog’s pancreas.
  • In 1926, Wilder-et-al associated hyperinsulinism and functional islet tumor after a surgery on a person who had hypoglycemia and found an islet cell cancer with liver metastasis.[2]
  • In 1927, William J Mayo was the first to discover the association between hyperinsulinism and a functional pancreatic islet cell tumor. In 1927, the insulinoma was first described in Mayo clinic, which was dissected in 1929 in Toronto.[1]
  • In 1929, the first surgical cure was performed by Roscoe Graham.[3]


Risk assessment table

Scoring criteria for risk assessment*
Scoring system Score Risk
IMPROVEDD Score Predicted % VTE risk through 42 days
0 0.4%
1 0.6%
2 0.8%
3 1.2%
4 1.6%
5-10 2.2%
Predicted % VTE risk through 77 days
0 0.5%
1 0.7%
2 1.0%
3 1.4%
4 1.9%
5-10 2.75
Padua Score < 4 Low risk for VTE
≥ 4 High risk for VTE
IMPROVE score Predicted % VTE risk through 3 months
0 0.5%
1 1.0%
2 1.7%
3 3.1%
4 4%
5-8 11%
Caprini score 0-1 Low risk of VTE
2 Moderate of VTE
3-4 High risk of VTE
≥ 5 Highest risk for VTE

References

  1. 1.0 1.1 Stamatakos M, Safioleas C, Tsaknaki S, Safioleas P, Iannescu R, Safioleas M (2009). "Insulinoma: a rare neuroendocrine pancreatic tumor". Chirurgia (Bucur). 104 (6): 669–73. PMID 20187464.
  2. Wilder, Russell M.; Allan, Frank N.; Power, M. H.; Robertson, H. E. (1927). "CARCINOMA OF THE ISLANDS OF THE PANCREAS". Journal of the American Medical Association. 89 (5): 348. doi:10.1001/jama.1927.02690050014007. ISSN 0002-9955.
  3. 3.0 3.1 Whipple AO, Frantz VK (1935). "ADENOMA OF ISLET CELLS WITH HYPERINSULINISM: A REVIEW". Ann. Surg. 101 (6): 1299–335. PMC 1390871. PMID 17856569.